Curevac doses first participant in phase 1 study with multivalent influenza vaccine candidate based on second-generation mrna backbone developed in collaboration with gsk

- multivalent technology approach for seasonal influenza mrna vaccine candidate addressing four different influenza strains - influenza candidate developed in collaboration with gsk within broad infectious disease vaccine program tÜbingen, germany and boston, ma / accesswire / february 10, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that it has dosed the first participant in a phase 1 study of its seasonal influenza second-generation mrna vaccine candidate, cvsqiv, developed in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking